drugset / Trial / NCT03378063
Stem Cells for Bronchopulmonary Dysplasia
Phase 0
Withdrawn
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Children's Hospital of Chongqing Medical University · collabChongqing Maternal and Child Health Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Very preterm infants are at high risk to develop to bronchopulmonary dysplasia (BPD) for the lack of effective measures to prevent or ameliorate this common and serious disorder. BPD remains a major cause of mortality and lifelong morbidity in preterm infants
Timeline
- Start
- 2017-11-01
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
Outcome
Outcome not reported
Stopped: “no stell cell accessed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human umbilical cord blood (hUCB)-derived mesenchymal stem cell | Cell therapy | — | — |